Sloboda A E, Tolman E L, Osterberg A C, Panagides J
Arzneimittelforschung. 1980;30(4A):716-21.
gamma-Oxo(1,1'-biphenyl)-4-butanoic acid (fenbufen) was shown to be an orally and parenterally effective nonsteroidal antiinflammatory, analgesic and antipyretic agent in a variety of animal species. Like other clinically active antiinflammatory drugs such as acetylsalicylic acid (ASA), indometacin and phenylbutazone, fenbufen has demonstrated potent activity in a variety of laboratory test systems including carageenin edema (rats), UV erythema (guinea pigs), adjuvant arthritis (rats), urate synovitis (dogs), phenylquinone writhing (mice), and yeast-induced pyresis (rats). In general, fenbufen was less potent than indomethacin and more potent than ASA, and appeared of special interest because of its high analgetic efficacy and long duration of antiinflammatory and analgetic action. While shown to have ulcerogenic potential in rats at toxic doses, fenbufen was less potent than indometacin in this respect and had a superior margin of gastrointestinal safety in treatment of dogs with urate synovitis. One of fenbufen's major metabolites, 4-biphenylacetic acid (BPAA), was found to be potent inhibitor of prostaglandin (PG) synthesis both in vitro and in vivo with a variety of tissues tested. Fenbufen itself was devoid of this anti-PG-synthetase activity although it interacted with prostaglandins in other ways. These results, coupled with the fact that only BPAA showed pharmacological activities when applied locally, led to the conclusion that BPAA was the principle responsible for fenbufen's antiinflammatory action. Fenbufen thus appears to be a pro-drug capable of circumventing at least some of the gastric toxicity usually incurred when compounds, which are themselves capable of inhibiting PG synthesis, are introduced directly into the stomach. Fenbufen's relatively low gastric toxicity in dogs and humans seems to substantiate this hypothesis. The pharmacological evidence indicates that fenbufen should be a highly effective and clinically useful antiinflammatory, analgetic and antipyretic drug.
γ-氧代(1,1'-联苯)-4-丁酸(芬布芬)在多种动物物种中显示出经口服和注射给药均有效的非甾体抗炎、镇痛和解热作用。与其他临床活性抗炎药物如乙酰水杨酸(ASA)、吲哚美辛和保泰松一样,芬布芬在多种实验室测试系统中均表现出强效活性,包括角叉菜胶性水肿(大鼠)、紫外线红斑(豚鼠)、佐剂性关节炎(大鼠)、尿酸盐滑膜炎(犬)、苯醌扭体反应(小鼠)以及酵母诱导的发热(大鼠)。总体而言,芬布芬的效力低于吲哚美辛而高于ASA,因其高镇痛效力以及抗炎和镇痛作用的持续时间长而显得特别引人关注。虽然在大鼠中毒剂量下显示有产生溃疡的潜在可能性,但在这方面芬布芬的效力低于吲哚美辛,并且在治疗尿酸盐滑膜炎犬时具有更高的胃肠道安全性。芬布芬的主要代谢产物之一,4-联苯乙酸(BPAA),在体外和体内对多种测试组织均被发现是前列腺素(PG)合成的强效抑制剂。芬布芬本身没有这种抗PG合成酶活性,尽管它以其他方式与前列腺素相互作用。这些结果,再加上仅BPAA局部应用时显示出药理活性这一事实,得出结论认为BPAA是芬布芬抗炎作用的主要负责成分。因此,芬布芬似乎是一种前体药物,能够规避至少一些当本身能够抑制PG合成的化合物直接引入胃中时通常会产生的胃毒性。芬布芬在犬和人类中相对较低的胃毒性似乎证实了这一假说。药理学证据表明芬布芬应该是一种高效且临床上有用的抗炎、镇痛和解热药物。